4.6 Article

The lymphotoxin-β receptor is an upstream activator of NF-κB-mediated transcription in melanoma cells

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 283, 期 22, 页码 15399-15408

出版社

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M708272200

关键词

-

资金

  1. NCI NIH HHS [R01 CA098807-03, R01 CA098807, CA 56704, CA 68485, CA 098807, P30 CA068485] Funding Source: Medline
  2. NHLBI NIH HHS [T32 HL007751, T30 HL 07751] Funding Source: Medline
  3. NIAMS NIH HHS [SP30 AR 1943] Funding Source: Medline
  4. BLRD VA [IK6 BX005225] Funding Source: Medline

向作者/读者索取更多资源

The pleiotropic transcription factor nuclear factor-kappa B (NF-kappa B (p50/p65)) regulates the transcription of genes involved in the modulation of cell proliferation, apoptosis, and oncogenesis. Furthermore, a host of solid and hematopoietic tumor types exhibit constitutive activation of NF-kappa B (Basseres, D. S., and Baldwin, A. S. (2006) 25,6817-6830). However, the mechanism for this constitutive activation of NF-kappa B has not been elucidated in the tumors. We have previously shown that NF-kappa B-inducing kinase (NIK) protein and its association with Inhibitor of kappa B kinase alpha beta are elevated in melanoma cells compared with their normal counterpart, leading to constitutive activation of NF-kappa B. Moreover, expression of dominant negative NIK blocked this base-line NF-kappa B activity in melanoma cells. Of the three receptors that require NIK for activation of NF-kappa B only the lymphotoxin-beta receptor (LT beta-R) is expressed in melanoma. We show in this manuscript that for melanoma there is a strong relationship between expression of the LT beta-R and constitutive NF-kappa B transcriptional activity. Moreover, we show that activation of the LT beta-R can drive NF-kappa B. activity to regulate gene expression that leads to enhanced cell growth. The inhibition by LT beta-R shRNA resulted in decreased NF-kappa B promoter activity, decreased growth, and decreased invasiveness as compared with control. These results indicate that the LT beta-R constitutively induces NF-kappa B activation, and this event maybe associated with autonomous growth of melanoma cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Dermatology

Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling

Jeffrey S. Pawlikowski, Claire Brock, Sheau-Chiann Chen, Lara Al-Olabi, Colin Nixon, Fiona McGregor, Simon Paine, Estelle Chanudet, Wendy Lambie, William M. Holmes, James M. Mullin, Ann Richmond, Hong Wu, Karen Blyth, Ayala King, Veronica A. Kinsler, Peter D. Adams

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)

Article Cell Biology

Slx5/Slx8 Promotes Replication Stress Tolerance by Facilitating Mitotic Progression

Yee Mon Thu, Susan Kaye Van Riper, LeeAnn Higgins, Tianji Zhang, Jordan Robert Becker, Todd William Markowski, Hai Dang Nguyen, Timothy Jon Griffin, Anja Katrin Bielinsky

CELL REPORTS (2016)

Article Biochemistry & Molecular Biology

Flap endonuclease overexpression drives genome instability and DNA damage hypersensitivity in a PCNA-dependent manner

Jordan R. Becker, David Gallo, Wendy Leung, Taylor Croissant, Yee Mon Thu, Hai Dang Nguyen, Timothy K. Starr, Grant W. Brown, Anja-Katrin Bielinsky

NUCLEIC ACIDS RESEARCH (2018)

Article Oncology

Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells

Anna E. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, Kevin P. Weller, Linda W. Horton, Colt M. McClain, Gregory D. Ayers, David C. Turner, David C. Essaka, Clinton F. Stewart, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey A. Ecsedy, Jeffrey N. Johnston, Ann Richmond

CANCER RESEARCH (2015)

Editorial Material Medicine, Research & Experimental

Th9 and Th17 cells: the controversial twins in cancer immunity

Chi Yan, Ann Richmond

JOURNAL OF CLINICAL INVESTIGATION (2020)

Article Biochemistry & Molecular Biology

Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer

Chi Yan, Jinming Yang, Nabil Saleh, Sheau-Chiann Chen, Gregory D. Ayers, Vandana G. Abramson, Ingrid A. Mayer, Ann Richmond

Summary: The study identified that combining PI3K/mTOR inhibitors with paclitaxel can enhance response to immune checkpoint inhibitors, leading to a positive impact on breast cancer treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Zoology

Students' Perceptions of FSBio 201, A CURE-Based Course that Scaffolds Research and Scientific Communication, Align with Learning Outcomes

Yee Mon Thu, Lauren B. French, Bradley M. Hersh, Margaret K. Nelson, Lisa B. Whitenack

Summary: The study explores the incorporation of research opportunities into undergraduate curricula, using FSBio 201 as an example. While student feedback is mostly positive, areas for improvement in peer mentoring and teaching computer skills are identified.

INTEGRATIVE AND COMPARATIVE BIOLOGY (2021)

Review Oncology

Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy

Kennady Bullock, Ann Richmond

Summary: The translation introduced the research progress of inhibiting MDSCs by blocking CXCR2 to enhance the response to immunotherapy. MDSCs are associated with poor responses to cancer therapy, while CXCR2 is a key factor in recruiting MDSCs to tumors.

CANCERS (2021)

Article Oncology

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients

Chi Yan, Sheau-Chiann Chen, Gregory D. Ayers, Caroline A. Nebhan, Joseph T. Roland, Vivian L. Weiss, Douglas B. Johnson, Ann Richmond

Summary: Resistance to BRAF/MEK-targeted therapy is common in melanoma patients with BRAF mutated tumors, and tumor cellularity is associated with immune cells and survival outcomes.

NPJ PRECISION ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer

Zhizhu Zhang, Ann Richmond, Chi Yan

Summary: Hyperactivation of PI3K/AKT/mTOR and MAPK/MEK/ERK signaling pathways is common in various cancers, and targeting these pathways may enhance the response to immune checkpoint inhibitors (ICIs) as a strategy to overcome resistance.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma

Chi Yan, Caroline A. Nebhan, Nabil Saleh, Rebecca Shattuck-Brandt, Sheau-Chiann Chen, Gregory D. Ayers, Vivian Weiss, Ann Richmond, Anna E. Vilgelm

Summary: Humanized PDX mouse models with reduced development of GVHD were generated, allowing for preclinical trials with immune checkpoint inhibitors.

CANCERS (2023)

Article Oncology

Loss of Vascular Endothelial Glutaminase Inhibits Tumor Growth and Metastasis, and Increases Sensitivity to Chemotherapy

Verra M. Ngwa, Deanna N. Edwards, Yoonha Hwang, Breelyn Karno, Xiaoyong Wang, Chi Yan, Ann Richmond, Dana M. Brantley-Sieders, Jin Chen

Summary: The metabolism of glutamine in tumor endothelium plays a crucial role in tumor growth and metastasis. Inhibiting glutamine metabolism can normalize tumor vessels, reduce tumor growth and metastasis, improve perfusion, reduce hypoxia, and enhance chemotherapeutic drug delivery.

CANCER RESEARCH COMMUNICATIONS (2022)

Article Oncology

Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity

Jinming Yang, Chi Yan, Anna E. Vilgelm, Sheau-Chiann Chen, Gregory D. Ayers, Christopher A. Johnson, Ann Richmond

Summary: The inhibition of the CXCR2 signaling pathway can reduce the number of MDSC in the tumor microenvironment, increase CXCL11-expressing B1b cells, and subsequently promote the infiltration and activation of effector CD8(+) T cells in tumors.

CANCER IMMUNOLOGY RESEARCH (2021)

暂无数据